Drug firms SeQuent Scientific and Shasun Pharmaceuticals, on Saturday, said they had signed a letter of intent to form a joint venture company to manufacture, develop and sell veterinary products. The products will include active pharmaceutical ingredients (APIs), and formulations will be sold globally, both companies said in a joint statement. As per the letter of intent (LoI), SeQuent will own 73 per cent of the joint venture company (JVC) while Shasun will own the remaining 27 per cent, it added.
This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every
month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
You have read {{data.cm.views}} out of {{data.cm.maxViews}} free articles.
This is your last free article.